User login
Recently, when The Dr. Oz Show’s Dr. Mehmet Oz turned to his television audience to ask if anyone had heard of transcranial magnetic stimulation (TMS) after a demonstration of its effectiveness in treatment-resistant depression (TRD), no one in the audience raised their hands.
I wonder why Drs. Desseilles, Fava, Mischoulon, and Freeman did not discuss TMS as an important choice for TRD in their article (“Personalizing depression treatment: 2 clinical tools,” Current Psychiatry, March 2012, p. 26-33). Harvard Medical School has done trials of TMS and McLean Hospital has created a positive video on TMS.
Andrew Krompier, MD
Private Practice
San Ramon, CA
Recently, when The Dr. Oz Show’s Dr. Mehmet Oz turned to his television audience to ask if anyone had heard of transcranial magnetic stimulation (TMS) after a demonstration of its effectiveness in treatment-resistant depression (TRD), no one in the audience raised their hands.
I wonder why Drs. Desseilles, Fava, Mischoulon, and Freeman did not discuss TMS as an important choice for TRD in their article (“Personalizing depression treatment: 2 clinical tools,” Current Psychiatry, March 2012, p. 26-33). Harvard Medical School has done trials of TMS and McLean Hospital has created a positive video on TMS.
Andrew Krompier, MD
Private Practice
San Ramon, CA
Recently, when The Dr. Oz Show’s Dr. Mehmet Oz turned to his television audience to ask if anyone had heard of transcranial magnetic stimulation (TMS) after a demonstration of its effectiveness in treatment-resistant depression (TRD), no one in the audience raised their hands.
I wonder why Drs. Desseilles, Fava, Mischoulon, and Freeman did not discuss TMS as an important choice for TRD in their article (“Personalizing depression treatment: 2 clinical tools,” Current Psychiatry, March 2012, p. 26-33). Harvard Medical School has done trials of TMS and McLean Hospital has created a positive video on TMS.
Andrew Krompier, MD
Private Practice
San Ramon, CA